Hanst Schambye News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The potential first-in-class, oral, lysyl oxidase-like 2 inhibitor GB2064 displayed efficacy with a generally acceptable tolerability profile in the treatment of patients with myelofibrosis.

City ofUnited kingdomClaire harrisonHanst schambyeDynamic international prognostic scoringGalecto incSafety review committeeTotal symptom scorePhase 2a mylox 1 trial nct04679870Lysyl oxidase like 2 inhibitor